开发KOOSglobal平台用于测量前交叉韧带重建术后患者报告结局
基于1904例前交叉韧带重建患者术前和术后2年的KOOS问卷应答,将KOOS关节置换简表(KOOS, JR)与4个KOOS生活质量问题合并构建KOOSglobal综合评分,并与IKDC主观评分进行心理测量学比较;KOOSglobal与IKDC显著相关(ρ=0.91,P<.001),解释了IKDC评分83%的变异,相对效率为0.63,术后满分率11%仍低于15%的 ceiling 效应阈值。
要点
- KOOSglobal由KOOS, JR与4个KOOS生活质量问题共11个条目组成,基于1904例前交叉韧带重建患者数据开发。
- KOOSglobal与IKDC评分显著相关(ρ=0.91,P<.001),解释IKDC评分83%的变异,相对效率0.63。
- KOOSglobal术后满分率为11%(213/1904),低于15%的ceiling效应阈值,而IKDC为6%。
核心结论
- KOOS多个亚量表在较年轻、更活跃的前交叉韧带人群存在较大ceiling效应,限制其使用。
- 由KOOS, JR与4个KOOS生活质量问题构建的11条目KOOSglobal是前交叉韧带重建术后反应良好的患者报告结局工具,与IKDC捕获的信息趋同。
- KOOSglobal可通过单一问卷计算多个评分,可能为骨科界提供一个跨膝相关亚专业的单一患者报告结局平台。
研究设计与样本
- 队列研究(诊断性),证据等级2级。
- 基于1904例接受前交叉韧带重建患者术前和术后2年对KOOS问卷的应答,构建KOOSglobal综合评分。
- 注册号:NCT00478894(ClinicalTrials.gov标识)。
主要发现
- KOOSglobal与IKDC评分显著相关(ρ=0.91,P<.001),解释IKDC评分83%的变异。
- KOOSglobal的相对效率为0.63,反应性与IKDC相似。
- KOOSglobal术后满分率为11%(213/1904),IKDC术后满分率为6%,KOOSglobal仍低于15%的ceiling效应阈值。
关键数值与推荐
- 收敛效度采用Spearman相关系数(ρ)评估。
- 反应性通过计算术前至术后的效应量和相对效率评估。
- 术前floor效应或术后ceiling效应定义为分别有15%的患者报告最差可能评分(KOOSglobal和IKDC为0分)或最佳可能评分(KOOSglobal和IKDC为100分)。
临床怎么用
- KOOSglobal可作为前交叉韧带重建术后患者报告结局的评估工具,与IKDC信息趋同。
- KOOSglobal可能为骨科界提供一个跨膝相关亚专业的单一患者报告结局平台。
局限性
- KOOS多个亚量表在较年轻、更活跃的前交叉韧带人群存在较大ceiling效应,限制其使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Knee injury and Osteoarthritis Outcome Score (KOOS) has demonstrated inferior psychometric properties when compared with the International Knee Documentation Committee (IKDC) subjective knee form when assessing outcomes after anterior cruciate ligament (ACL) reconstruction. The KOOS, Joint Replacement (KOOS, JR) is a validated short-form instrument to assess patient-reported outcomes (PROs) after knee arthroplasty, and the purpose of this study was to determine if augmenting the KOOS, JR with additional KOOS items would allow for the creation of a short-form KOOS-based global knee score for patients undergoing ACL reconstruction, with psychometric properties similar to those of the IKDC. HYPOTHESIS: An augmented version of the KOOS, JR could be created that would demonstrate convergent validity with the IKDC but avoid the ceiling effects and limitations previously noted with several of the KOOS subscales. STUDY DESIGN: Cohort study (diagnosis); Level of evidence, 2. METHODS: Based on preoperative and 2-year postoperative responses to the KOOS questionnaires from a sample of 1904 patients undergoing ACL reconstruction, an aggregate score combining the KOOS, JR and the 4 KOOS Quality of Life subscale questions, termed the KOOSglobal, was developed. Psychometric properties of the KOOSglobal were then compared with those of the IKDC subjective score. Convergent validity between the KOOSglobal and IKDC was assessed with a Spearman correlation (ρ). Responsiveness of the 2 instruments was assessed by calculating the pre- to postoperative effect size and relative efficiency. Finally, the presence of a preoperative floor or postoperative ceiling effect was defined with the threshold of 15% of patients reporting either the worst possible (0 for KOOSglobal and IKDC) or the best possible (100 for KOOSglobal and IKDC) scores, respectively. RESULTS: The newly developed KOOSglobal was responsive after ACL reconstruction and demonstrated convergent validity with the IKDC. The KOOSglobal significantly correlated with the IKDC scores (ρ = 0.91, P < .001), explained 83% of the variability in IKDC scores, and was similarly responsive (relative efficiency = 0.63). While there was a higher rate of perfect postoperative scores with the KOOSglobal (213 of 1904, 11%) than with the IKDC (6%), the KOOSglobal was still below the 15% ceiling effect threshold. CONCLUSION: The large ceiling effects limit the ability to use several of the KOOS subscales with the younger, more active ACL population. However, by creating an aggregate score from the KOOS, JR and 4 KOOS Quality of Life subscale questions, the 11-item KOOSglobal offers a responsive PRO tool after ACL reconstruction that converges with the information captured with the IKDC. Also, by offering the ability to calculate multiple scores from a single questionnaire, the KOOSglobal may provide the orthopaedic community a single PRO platform to be used across knee-related subspecialties. Registration: NCT00478894 ( ClinicalTrials.gov identifier).
引用
- Jacobs CA, Peabody MR, Lattermann C, et al. Development of the KOOSglobal Platform to Measure Patient-Reported Outcomes After Anterior Cruciate Ligament Reconstruction. Am J Sports Med. 2018. PMID: 30074823. doi:10.1177/0363546518789619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。